Physician profile
Eric M Sincoff
NPI 1730679010
$4,465.45
in general payments reported to CMS, 2019-2025
33 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $1,496 · 2023: $2,148 · 2024: $537 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,786.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $633.09 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $574.62 | 2022-2024 | Repatha, Otezla, Prolia |
| Abbvie INC. | $547.89 | 2021-2024 | Vraylar, Ubrelvy |
| Pfizer INC. | $350.94 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $346.08 | 2022-2024 | |
| Lilly USA, LLC | $339.70 | 2022-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $339.34 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $229.74 | 2021-2023 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $207.85 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.23 | 2022-2024 | Jardiance, Synjardy |
| Biohaven Pharmaceutical Holding Company LTD. | $83.31 | 2022 | |
| Astellas Pharma US INC | $56.80 | 2022-2023 | Myrbetriq |
| Janssen Pharmaceuticals, INC | $48.62 | 2022 | |
| Alnylam Pharmaceuticals INC. | $46.69 | 2022-2023 | Givlaari |
| Teva Pharmaceuticals USA, INC. | $45.24 | 2023 | Ajovy, Austedo Xr |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $37.28 | 2021 | |
| Exact Sciences Corporation | $36.39 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $36.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $35.09 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $26.36 | 2023 | Quviviq |
| Corcept Therapeutics | $25.18 | 2024 | Korlym |
| Abbott Laboratories | $24.83 | 2025 | Eterna |
| Ascensia Diabetes Care US INC. | $24.50 | 2024 | |
| Gilead Sciences, INC. | $23.50 | 2024 | |
| Genzyme Corporation | $20.66 | 2023 | |
| Bausch Health US, LLC | $19.57 | 2023 | Wellbutrin, Aplenzin |
| Lundbeck LLC | $19.47 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.66 | 2023 | Xifaxan |
| Dexcom, INC. | $18.64 | 2023 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $17.96 | 2024 | Loreev Xr |
| Medtronic, INC. | $16.99 | 2023 | Intellis Adaptivestim |
| Amarin Pharma, INC. | $16.73 | 2021 | |
| Edwards Lifesciences Corporation | $15.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sincoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.